Multicenter, prospective interventional study to evaluate therapeutic effect of Afatinib in patients with advanced non-small cell lung cancer, EGFR mutation positive and brain metastasis - Afatinib MET-PET/CT Study

Hanaoka Masayuki0 个研究点目标入组 1 人开始时间: 2019年3月13日最近更新: 2023年10月17日

适应症

试验速览

Afatinib was reduced SUVmax and LNRmax rate of metastases to brain.

•1)Histologically or cytologically confirmed diagnosis of non-squamous cell and non-small cell lung cancer
•2)Stage IV advanced unresectable, postoperative recurrent cancer
•3)To detect following mutations by analysis of tissue or cell sample
•4)Deletion in exon19 or L858R point mutation in exon 21 of EGFR gene
•5)Brain metastasis verified by MRI or CT and >= 10 mm measurably
•6)Using afatinib as first line treatment.
•7)Age >= 20 years at obtained informed consent
•8)ECOG performance status 0-2
•9)The function of organs (marrow,liver,kidney,etc.)is maintained enough
•10)Life expectancy >= 3 months

•1)Idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug pneumonia, etc. are complicated
•2)Active other malignancy
•3)Adjuvant chemotherapy
•4)Infection to need to treat with antibiotics or antifungal agent via intravenous administration

发起方

Hanaoka Masayuki